Why is Astronics stock sliding today?

Astronics (ATRO) stock fell 10% premarket after Q4 revenue guidance of $255M-$275M missed estimates. Q3 results beat expectations with $1.08 EPS and $271.7M revenue. CEO cited strong demand but noted supply chain issues. Analysts maintain 'Moderate Buy' rating with $89.58 target.

Original reporting
Published Nov 11, 2026, 1:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 1:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$ATRO
Bearish
high confidence
Mentioned
$ATRO
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ATROBearishHigh
01

Why it matters

The guidance shortfall directly drove a 10% price decline, suggesting immediate trading opportunities.

02

Market read

Guidance miss creates short‑term downside risk for ATRO and may influence sentiment toward similar aerospace suppliers.

03

What to watch

Backlog growth and record Q3 margins may support longer‑term upside despite short‑term guidance miss.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Astronics reported strong Q3 results but issued a cautious Q4 outlook, prompting a sharp pre‑market sell‑off.

Company-level read

Ticker impact

$ATROBearishHigh confidence
Context

Astronics stock slid ~10% in pre‑market trading after the company issued Q4 revenue guidance of $255‑$275 million, below consensus.

Expected impact

likely further downside as investors price in lower revenue outlook

Evidence & confidence

The guidance shortfall is material and caused an immediate 10% pre‑open decline, indicating strong market reaction.

Market effects

Aerospace & defense suppliers may see heightened scrutiny on guidance forecasts.

U.S. tech‑focused investors may rotate out of small‑cap aerospace stocks.

Limited; impact confined to U.S. equity markets and sector peers.

Counterpoint

If the Q3 beat signals strong underlying demand, the guidance dip could be a temporary overreaction.

Key entities

  • Astronics Corporation

    Aerospace and defense technology supplier (NASDAQ: ATRO).

Related articles

$CRWVHighAI 8/10

CoreWeave, Fossil Rally as BrightView Shares Plunge

CoreWeave (CRWV) shares rose 23.5% after Q3 revenue of $3.66B beat estimates and FY guidance was raised. Fossil Group (FOSL) shares jumped 28% on Q3 profit beat and raised FY outlook. BrightView (BV) shares fell 15.5% after Q4 earnings and revenue missed estimates. Astronics (ATRO) shares gained 1.1% on Q3 earnings beat despite weaker Q4 revenue outlook. Costco announced a $30 special dividend and $4B share repurchase program.

$CRWVMed

Futures Rise As CoreWeave Calms Debt Jitters, Sparking AI Rebound; Oil Jumps On Hormuz Mines

US futures rise as CoreWeave (CRWV) boosts its revenue forecast, easing debt concerns. AI sector gains momentum with reports of Anthropic's potential $1.5T IPO and OpenAI's $10B quarterly revenue. Nasdaq futures recover Tuesday's losses, while Treasuries near 5% on 10Y. Oil jumps on Strait of Hormuz tensions. CoreWeave shares up 15% premarket. NVDA +5.1%, TSLA +2%, GOOGL +1.2%.

$ATROMed

Astronics Corp (ATRO) (Q3 2026) Earnings Call Highlights: Record Sales and Profitability

Astronics Corp (ATRO) reported Q3 2026 earnings with record sales and profitability. Q4 revenue guidance is $255-$275M, a sequential decline, due to customer scheduling and market uncertainties. Supply chain concerns, particularly for memory modules, were noted. The MV-75 program's rescheduling creates uncertainty. Test Systems bookings were lumpy. Macroeconomic and geopolitical risks, like the war in Iran, could impact airline profitability.

$ATROMedAI 8/10

Astronics (ATRO) Q3 2026 Earnings Call Transcript

Astronics (ATRO) reported Q3 2026 earnings with record sales of $272M, up 28.5% YoY. Aerospace segment sales reached $246M, while Test segment sales were $26M. Operating income doubled to $54M, with adjusted EBITDA margin at 21.8%. The company cited strong demand and cost-cutting measures for the growth.